Literature DB >> 23256761

Crohn's as an immune deficiency: from apparent paradox to evolving paradigm.

Donald C Vinh1, Marcel A Behr.   

Abstract

Crohn's disease is often considered an autoimmune condition, based on the observations of a histopathological inflammatory process in the absence of identifiable causal microorganism(s) and that immune-modulating therapeutics result in diminished host-directed inflammatory pathology. However, the evidence for a self-targeted immune response is unproven; thus, the instigating and perpetuating forces that drive this chronic inflammation remain unknown. In recent years, a convergence of findings from different fields of investigation has led to a new paradigm, where Crohn's disease appears to be the consequence of an intrinsic innate immune deficiency. While genomic/postgenomic studies and functional immunologic investigations offer a common perspective, critical details of the processes involved require further elaboration. In this review, we place this new model in the context of the emerging literature on non-HIV immune deficiencies, to compare and contrast what is known about proven intrinsic (primary) immune deficiencies to the nascent understanding of Crohn's disease. We then re-evaluate postgenomic research, looking at the functional importance of Crohn's disease-associated mutations and polymorphisms, to delineate points of consensus and issues requiring further study. We ask whether the immunologic profile can guide predictions as to which microbial triggers could exploit these defects and thereby initiate and/or perpetuate chronic enteritis. Finally, we outline potential clinical implications of this model, from immunologic assessment of patients to the selection of therapeutic interventions.

Entities:  

Mesh:

Year:  2013        PMID: 23256761     DOI: 10.1586/eci.12.87

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  7 in total

1.  Complex partial status epilepticus in a patient with Crohn's disease.

Authors:  Montserrat G Delgado; Juan Vega; Elena Santamarta; Luis Caminal
Journal:  BMJ Case Rep       Date:  2013-09-06

Review 2.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 3.  What is wrong with granulocytes in inflammatory bowel diseases?

Authors:  Adam P Levine; Anthony W Segal
Journal:  Dig Dis       Date:  2013-11-14       Impact factor: 2.404

4.  Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.

Authors:  Brian Bressler; Kevin P Bethel; Ralf Kleef; Sophie L Reynolds; Simon Sutcliffe; David W Mullins; Hal Gunn
Journal:  Gastroenterol Res Pract       Date:  2015-05-12       Impact factor: 2.260

5.  Dietary Fiber Intake is Associated with Increased Colonic Mucosal GPR43+ Polymorphonuclear Infiltration in Active Crohn's Disease.

Authors:  Mingli Zhao; Weiming Zhu; Jianfeng Gong; Lugen Zuo; Jie Zhao; Jing Sun; Ning Li; Jieshou Li
Journal:  Nutrients       Date:  2015-07-01       Impact factor: 5.717

Review 6.  Intestinal Barrier Interactions with Specialized CD8 T Cells.

Authors:  Špela Konjar; Cristina Ferreira; Birte Blankenhaus; Marc Veldhoen
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

7.  Disruption of macrophage pro-inflammatory cytokine release in Crohn's disease is associated with reduced optineurin expression in a subset of patients.

Authors:  Andrew M Smith; Gavin W Sewell; Adam P Levine; Thean S Chew; Jenny Dunne; Nuala R O'Shea; Philip J Smith; Penelope J Harrison; Carol M Macdonald; Stuart L Bloom; Anthony W Segal
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.